Fabio Pammolli

  +39 0583 4326 551

Fabio Pammolli photo

PERSONAL INFORMATION

Fabio Pammolli

Full Professor, Economics and Management, IMT Institute for Advanced Studies, Lucca (www.imtlucca.it)

Home Via del Campaccio, 950, Località Gattaiola, LUCCA, 55100, Italy

Institutional mail address: Prof. Fabio Pammolli, IMT Alti Studi Lucca

Piazza San Francesco, 19 - LUCCA, 55100, Italy

+39 0583 4326 551

+39 348 8120691

pammolli@gmail.com

 

 Personal mail address for any administrative communication

Fabio Pammolli, Corso Tassoni, 32, TORINO, 10143

Homepage: http://www.imtlucca.it/fabio.pammolli

Date of birth 11/01/1965 | Nationality Italian

 

PROFESSIONAL EXPERIENCE

November 2004 – onwards: Pammolli is Professor of Economics and Management at IMT (Institutions, Markets, Technologies) Institute for Advanced Studies Lucca, where he has launched and directed, until April 2016, the new Ph.D. in Economics, Management, and Data Sciences, a multidisciplinary program focused on the development and application of analytical techniques in economics and management science.

Starting from Jan 1, 2016, he holds a position of senior scientist at IIT, the Italian Institute of Technology, coordinating the set up of a joint center between IIT and Politecnico di Milano on socio economic analysis and translational modelling (CADS, Center on Analysis, Decisions, and Society).

At IMT Lucca, he holds the Chair of Management Science and Corporate Finance, and he serves as the Director of the research unit Axes (Analysis of compleX Economic Systems), coordinating a multidisciplinary team of assistant professors in management science, economics, statistical physics, computer science, and statistics.

In November 2015, he has been selected to serve as a member of the Investment Committee of the European Fund for Strategic Investments (EFSI) at the European Investment Bank, Luxembourg. The Investment Committee is responsible for examining potential projects in line with the EFSI investment policies and for approving the support of the EU guarantee for EIB operations, in the context of the so-called Juncker Plan.

In his research, Pammolli combines different methodologies to cover a variety of topics in economics and management of innovation, management analytics, economics and management of science and technology, the economics of health and pensions, and the analysis of growth, diversification, and instability of business firms. Specific recent research topics include the impact of firm diversification on growth intensity and volatility, the impact of alliances on R&D productivity, the structure of financial and control networks. Together with H.E. Stanley, S. Buldyrev, and M. Riccaboni, he is completing a book, on growth and instability of business firms (‘The Growth of Business Firms’, forthcoming with Cambridge University Press). Moreover, he has authored numerous publications on industry structure, innovation, and firm strategy in biotechnology and pharmaceuticals. Fabio authored several reports on Science and Technology Policy in the EU, for DG Enterprise. In his collaboration with Woody Powell at Stanford University, Fabio has developed a set of original techniques to analyze the competiveness and the specialization profiles of public and private research centers in the Life Sciences (see F. Pammolli, 2002, "A Comparison of U.S. and European University-Industry Relations in the Life Sciences", with J. Owen-Smith, W.W. Powell, M. Riccaboni, Management Science, 48(1), 24-43). In 2013, the paper “Is Europe Evolving Toward An Integrated Research Area” in Science  (http://www.sciencemag.org/content/339/6120/650.summary) has stimulated policy debate on the extent to which Europe can be considered an integrated research system, as well as on the programs that can be implemented to foster the competitiveness of European Science and Technology.

Pammolli served (2004-2012) as the Founding Director and President of the Executive Council (Board of Directors) of the newly founded IMT Institute for Advanced Studies (www.imtlucca.it), a public Italian graduate school. He has managed the startup and establishment of the Institute as one of the five Italian Schools for Advanced Studies, designing the scientific mission of the Institute sand its financial architecture and sustainability. He has mobilized, attracted and managed both public and private investments (about 7 M€ per year as a permanent funding from the State, plus an investment of about 65€M on Campus Facilities and Research/Education Services, from the Lucca Foundation for Research and Higher Education, which he contributed to conceive). As the founding Director of the Institute, he has presided over and directed its establishment as an international research university, which integrates education and research in the multidisciplinary analysis of a variety of socio-economic, engineering, and technological systems. Fabio served coordinating and presiding all the hiring committees for senior and junior faculty members, at the international level, across all the disciplinary fields covered by the Institute, from political economy to comparative law, applied economics, management science, control, statistical physics, computer science, and humanities. 

Cf. https://www.imtlucca.it/whats_new/_press_review_files/IHT_Simplifying_Italy_to_lure_global_graduates.pdf

Cf. also http://www.imtlucca.it/institute/press-media/headlines.

Moreover, cf. the reference to IMT in the MIT Report on the Formation of a New Entity in the Areas of Complex and Socio-technical Systems, Information and Decision Systems, and Statistics (PDF), at http://orgchart.mit.edu/node/6/pnr

 

Since 2012, Fabio is the scientific coordinator of Crisis Lab@IMT (www.crisislab.it) a multi year research project funded by the Italian Ministry of Education (Progetti di Rilevanza Nazionale, total funding 6M €) where IMT, in collaboration with the National Council of Research, has created a unique computational infrastructure and data repository to analyze the structure and evolution of a variety of economic systems in finance, energy, urban transport systems, industries and firms, scientific and technological systems, pension and health systems (www.crisislab.it http://www.crisislab.it/subprojects ), with a focus on systemic risk, instability and growth in economic systems, and science and technology policy.

He was a visiting scholar at Scancor, Stanford University, and at MIT. From September 2013 to September 2014, during his sabbatical leave, Fabio has visited four leading Universities in Europe and in the US. First, he was a Visiting Research Fellow, OFCE (Observatoire Français des Conjonctures Economiques), Sciences Po, Paris, France: main focus on long term projections and policy evaluation in health and pensions as well as on research and evaluation of public policies at large. He was then a Visiting research fellow, STICERD, The London School of Economics, London, UK: main focus on the relationship between specialization, diversification, growth, and instability of economic entities (firms, portfolios, regions, and countries), as well as on the economics of science and technology. In the US, he was a Visiting Scholar at the Department of Economics, Harvard University, Cambridge Ma. US: main focus on business firms growth and on economics of innovation. Finally, he was a Visiting Scholar at the Laboratory for Information and Decision Systems (LIDS), Massachusetts Institute of Technology, Cambridge Ma. US:  main focus: analytical methods for analysis and control of complex sociotechnical systems.

 

Since 2004 Fabio is a Research Fellow at the Department of Physics, Center for Polymer Studies, at Boston University, Boston US: main focus on business firms’ growth, network theory (ref. H.E. Stanley, S. Buldyrev).

From November 2001 until November 2004 he served as Full Professor of Economics and Management, University of Florence, Italy, holding the Chair of Economics and Management.

 

From November 1990 to November 2001 he was Assistant Professor (1990-1996) and then Associate Professor (1996-2004) of Economics and Management, University of Siena, Italy, where he taught several undergraduate classes in Corporate Finance, Economics of Strategy, Economics Organization and Management, Marketing Science. In Siena he set up the Industrial Liaison Office of the University, defining its architecture and the project evaluation procedures (IP policy, licensing contracts, attraction and evaluation of industrial partners and collaborative projects with industry). Main fields of activity: health and medicine, the life sciences and biotechnology, collaborations with SMEs. From 2001 to 2003 he served as the President of Toscana Life Sciences Science Park Organizing Committee, conceiving and designing the structure of the BioPark, completing its business plan, identifying core infrastructures and technological platforms, and selecting the first cohort of candidate projects. Visit http://www.toscanalifesciences.org/it/

 

Participation to Committees

2014: Member of the European Research Council SH1 Starting Grants Committee (economics and management).  

From 2012 to 2015: Ministry of Labour and Welfare, Italy: Member of the Expert Committee for the Assessment of Labor Market Reforms. Policy evaluation and impact analysis. Report on the impact of labour market reforms.

From 2011 to 2016: CNR Research Ethics and Bioethics Committee, the leading body on research integrity in Italy.

From 2011 to 2012: Ministry of Labour and Social Policies and Ministry of Economy and Finance:  Member of the Pension Expenditure Assessment Board: Impact analysis and long-term projections for public pensions expenditure. Report on pension expenditure sustainability. Support to the definition of benchmarks allocation and evaluation criteria for regional health care expenditure in Italy.

In 2011-2012: Member of the High Level Evaluation Committee set up by the Italian Government to perform an impact analysis of Rome’s candidature to organize the 2020 Olympic Games. The Report of the Committee, which covers an in depth analysis of both the micro and the macro economic of the Games, at the local and at the national level, is available at http://www.ilfoglio.it/media/uploads/2011/Olimpiadi(1).pdf

From 2003 to 2006: WHO (World Health Organization): Member of Commission on Intellectual Property Rights, Innovation and Public Health, with a focus on the assessment and the evaluation of alternative programs to improve access to medicines in Developing Countries, also in collaboration with the World Bank. In 2006, The Commission on Intellectual Property Rights, Innovation and Public Health published the Report " Public Health, Innovation and Intellectual Property Rights", World Health Organization, Geneva, Switzerland.  The report is available at: http://www.who.int/intellectualproperty/report/en/

From 2001 to 2006: Italian National Institutes of Health: Member of the Scientific Committee. Support to the Executive Council for project evaluation and strategic planning.

From 1998 to 2006: Ministry of Health and Ministry of Economy and Finance:  Member of the Committee on Pricing and Reimbursement for Pharmaceutical Products: Impact evaluation, cost benefit analysis, and price negotiations for reimbursement of new pharmaceutical products by the National Healthcare System.

 

EDUCATION

1988-1991: Corso di Perfezionamento in Economics and Management, Sant’Anna School for Advanced Studies, Pisa. During his doctoral studies, between 1990 and 1991, he spent one year as visiting student and then as a visiting scholar at Northeastern University, Boston, thanks to a NATO/NCR competitive grant.

 

1983-1987 Laurea Degree in Economics, University of Pisa.

 

1978-1983 Diploma Liceo Classico N. Machiavelli, Lucca.

 

 

LANGUAGE SKILLS

Mother tongue(s) ITALIAN

Other language(s)

 

ENGLISH

UNDERSTANDING C2

SPEAKING C2

WRITING C2

 

FRENCH

UNDERSTANDING C2

SPEAKING C1

WRITING C1

 

PUBLICATIONS h-index (Google Scholar), 32

 

Selected papers and reports

 

  1. F. Pammolli, 2016, ‘Learning from successes and failures in pharmaceutical R&D’, Journal of Evolutionary Economics, (with J.Y. Chiou, L. Magazzini, M. Riccaboni).
  2. F. Pammolli, Fabio, 2015, Real Options and Incremental Search in Pharmaceutical R&D Project Portfolio Management. Creativity and Innovation Management (with L. Magazzini and M. Riccaboni) ISSN 1467-8691.
  3. F. Pammolli, 2015, Systemic risk and banking regulation: some facts on the new regulatory framework.(with M.  Bonollo, I. Crimaldi, A. Flori, M. Riccaboni) Corporate Ownership & Control, 12 (2). pp. 52-63. ISSN 1727 - 9232 (2015)
  4. F. Pammolli, 2015, “ The evolution of networks of innovators within and across borders: Evidence from patent data”, (with A. Morescalchi, M. Riccaboni, O. Penner, A. Petersen),  Research Policy, Volume 44, Issue 3, April 2015, Pages 651–668
  5. F. Pammolli, 2015, Systemic risk and banking regulation: Some facts on the new regulatory framework. Corporate Ownership & Control, 12 (2). pp. 52-63. ISSN 1727 - 9232 (2015) (with M. Bonollo, I. Crimaldi, A. Flori and M. Riccaboni)
  6. F. Pammolli, 2015, Research and Development Alliances, in M. Augier, D. Teece (eds.) The Palgrave Encyclopedia of Strategic Manatement, Palgrave MacMillan, London,.
  7. F. Pammolli, 2015, Border sensitive centrality in global patent citation networks., with G. Morrison, E. Giovanis, M. Riccaboni) Journal of Complex Networks, 2 (4). pp. 518-536. ISSN 2051-1310
  8. F. Pammolli, 2014, Reputation and impact in academic careers. (with A. Petersen, H.E. Stanley, M. Riccaboni, O. Penner, S. Fortunato, R.K. Pan, K. Kaski), Proceedings of the National Academy of Sciences, 111 (43). pp. 15316-15321. ISSN 1091-6490.
  9. F. Pammolli, 2014, On Innovation, Instability, and Growth. A Review and an Interpretative Framework. Economia Politica, n. 1. Originally presented at the Fondazione Centesimus Annus - Pro Pontifice, 20th Anniversary International Conference: “Rethinking Solidarity for Employment: The Challenges of the Twenty-First Century”, Rome and The Vatican, May 23-25, 2013.
  10. F. Pammolli, 2014, Network communities within and across borders (with F. Cerina, A. Chessa, M. Riccaboni), Nature Scientific Reports, 4. pp. 1-7. ISSN 2045-2322 (2014).
  11. F. Pammolli, 2013, “Is Europe Evolving Toward an Integrated Research Area?” (with A. Chessa, A. Morescalchi, O. Penner, A. Petersen, M. Riccaboni). Science, 339 (6120). pp. 650-651. ISSN 0036-8075 (2013)
  12. F. Pammolli, 2013, Border sensitive centralities in patent citation networks using asymmetric random walks, (with G. Morrison, E. Giovanis and M. Riccaboni) In: International Conference on Signal-Image Technology & Internet-Based Systems (SITIS). IEEE, pp. 546-552. ISBN 978-1-4799-3211-5 (2013).
  13. F. Pammolli, 2013, Evolution of controllability in interbank networks. (with G. Caldarelli, S. Battiston, D. Delpini, M. Riccaboni, G. Gabbi) Nature Scientific Reports, 3 (1626). pp. 1-5. ISSN 2045-2322 (2013).
  14. F. Pammolli, 2013,  "Weighted networks as randomly reinforced urn processes" (with G. Caldarelli, A. Chessa, I. Crimaldi) Physical Review E, 87 (2). ISSN 1539-3755 (2013)
  15. F. Pammolli, 2013, Reconstructing a credit network. (with G. Caldarelli, A. Chessa, D. Delpini, M. Puliga, A. Gabrielli) Nature Physics, 9 (3). pp. 125-126. ISSN 1745-2473 (2013)
  16. F. Pammolli, 2012, Persistence and Uncertainty in the Academic Career. Proceedings of the National Academy of Sciences. (with A. M. Petersen, M. Riccaboni, H. E. Stanley), ISSN 1091-6490 (2012)
  17. - F. Pammolli, 2012, "Learning from Failures or Failing to Learn? Lessons from Pharmaceutical R&D", (with L. Magazzini, M. Riccaboni), European Management Review, 9(1), 45-58
  18. F. Pammolli, 2012, "The Sustainability of European Health Care Systems: Beyond Income and Ageing", (with M. Riccaboni, L. Magazzini), The European Journal of Health Economics, October 2012, Volume 13, Issue 5, pp 623-634
  19. F. Pammolli, 2011, “The productivity crisis in pharmaceutical R&D”, (with L. Magazzini, M. Riccaboni), Nature Reviews, vol. 10, 428-43
  20. F. Pammolli, 2011, "La distribuzione dei farmaci tra progetti di riforma e incertezze", (with N. C. Salerno), Economia e politica industriale, 38(2), 125-148.
  21. - F. Pammolli, 2010, "Scale-free models for the structure of business firm networks", (with M. Kitsak, M. Riccaboni, S. Havlin, H.E. Stanley), Physical Review E, vol. 81
  22.  - F. Pammolli, 2009, "Patent disclosure and R&D competition in pharmaceuticals", (with L. Magazzini, M. Riccaboni, M.A. Rossi), Economics of Innovation and New Technology, 18(5), 467–486
  23. F. Pammolli, 2009, "A Breath of Fresh Air? Firm Types, Scale, Scope and Selection Effects in Drug Development", (with A. Arora, A. Gambardella, L. Magazzini), Management Science, 55(10), 1638-1653
  24. F. Pammolli, 2008, "The Size Variance Relationship of Business Firm Growth Rates", (with S.V. Buldyrev, M. Riccaboni, H.E. Stanley, L. Ponta), Proceedings of the National Academy of Sciences, 105(50), 19595-19600
  25. F. Pammolli, 2008, "La Sanità in Italia - Federalismo, regolazione dei mercati, sostenibilità delle finanze pubbliche", (with N. C. Salerno), Il Mulino, Bologna.
  26. F. Pammolli, 2008, "Size dependent standard deviation for growth rates: Empirical results and theoretical modelling", (with B. Podobnik, D. Horvatic, F. Wang, H. E. Stanley, and I. Grosse), Physical Review E, 77(1)
  27. F. Pammolli, 2008, "On the Size Distribution of Business Firms", (with J. Growiec, M. Riccaboni, H.E. Stanley), Economics Letters, 98(2), 207-212
  28. F. Pammolli, 2008, " Il sistema pensionistico: quale riforma?", (with N. C. Salerno), parte II, cap.9, pp. 335 - 353 in: A cura di Luciano Guerzoni, La Riforma del Welfare - Dieci anni dopo la «Commissione Onofri», Il Mulino, Bologna
  29. F. Pammolli, 2008, "Regolazione di prezzo, innovazione e ciclo di vita dei prodotti: per una riforma del sistema di pricing nel settore farmaceutico", (with C. Bonassi, M. Riccaboni, N. C. Salerno), cap. III, pp 79-132 in "La salute e il mercato. La ricerca farmaceutica tra Stato, industria e cittadini", a cura di Giorgio Macciotta, collana Ricerche di Astrid, Il Sole 24 ORE, Milano
  30.  F. Pammolli, 2008, "La distribuzione al dettaglio dei farmaci: tra regolazione efficiente e mercato", (with N. C. Salerno), cap. VI, pp 153-198 in "La salute e il mercato. La ricerca farmaceutica tra Stato, industria e cittadini", a cura di Giorgio Macciotta collana Ricerche di Astrid, Il Sole 24 ORE, Milano
  31. F. Pammolli, 2007, "The Growth of Business Firms: Facts and Theory", (with S. V. Buldyrev, J. Growiec, M. Riccaboni, H. E. Stanley), Journal of the European Economic Association, 5(2/3), 574–584
  32. F. Pammolli, 2007, "Betweennes Centrality of Fractal and Non Fractal Scale Free Model Networks and Tests on Real Networks", (with M. Kitsak, S. Havlin. G. Paul, M. Riccaboni, H. E. Stanley), Physical Review E, 75(5)
  33. F. Pammolli, 2007, "Innovation and Industrial Leadership: Lessons from Pharmaceuticals", (with M. Riccaboni), Center for Transatlantic Relations, The Johns Hopkins University, Washington D.C.
  34. F.Pammolli, 2007, "Health Services in an Open Transatlantic Market: A European Perspective" (with M. Riccaboni, C. Bonassi), cap. IV, pp 77-97 in "Sleeping Giant – Awakening The Transatlantic Services Economy", edited by Daniel S. Hamilton and Joseph P. Quinlan, Center for Transatlantic Relations, The Johns Hopkins University, Washington D.C.
  35. F. Pammolli, 2007, "A Generalized Preferential Attachment Model for Business Firms Growth Rates: II. Mathematical Treatment", (with S.V. Buldyrev, M. Riccaboni, K. Yamasaki, D. Fu, K. Matia, H.E. Stanley), The European Physical Journal B, 57(2), 131–138
  36. F. Pammolli, 2007, "A Generalized Preferential Attachment Model for Business Firms Growth Rates. I. Empirical Evidence", (with D. Fu, S.V. Buldyrev, M. Riccaboni, K. Matia, K. Yamasaki, H.E. Stanley), The European Physical Journal B, 57 (2), 127–130
  37. F. Pammolli, 2007, Politiche di liberalizzazione e concorrenza in Italia, (with C. Cambini, A. Giannaccari), Il Mulino, Bologna
  38. F. Pammolli, 2007, "Spesa sanitaria, demografia, istituzioni", cap. 7, pp. 103-125 in A cura di M. Madìa, introduzione di E. Letta, Un Welfare Anziano - Invecchiamento della popolazione o ringiovanimento della società?, Il Mulino - Arel, Bologna
  39. -F. Pammolli, 2006, "Il sistema di istruzione italiano: un confronto internazionale", (with G. Papa, N.C. Salerno), vol. 13, parte I, cap. 4, pp. 81-125 in A cura di Paola Reggiani Gelmini, Michele Tiraboschi, Prefazione di Letizia Moratti, Scuola, Università e Mercato del lavoro dopo la Riforma Biagi - Le politiche per la transizione dai percorsi educativi e formativi al mercato del lavoro, Collana Adapt - Fondazione "Marco Biagi", Giuffré Editore, Milano
  40. F. Pammolli, 2006, "Preferential Attachment and Growth Dynamics in Complex Systems", (with K. Yamasaki, K. Matia, D. Fu, S. V. Buldyrev, M. Riccaboni, H. E. Stanley), Physical Review E, 74, 3, 035103(R)8
  41. Commission on Intellectual Property Rights, Innovation and Public Health, 2006, " Public Health, Innovation and Intellectual Property Rights", World Health Organization, Geneva, Switzerland.  The report is available at:  http://www.who.int/intellectualproperty/report/en/
  42. F. Pammolli, 2006, "Growth and Diversification Patterns of the Worldwide Pharmaceutical Industry", (with Giulio Bottazzi and Angelo Secchi), in G. Dosi e M. Mazzucato (eds), Knowledge Accumulation and Industry Evolution. The Case of Pharma-Biotech, Cambridge University Press, Cambridge, UK, pp. 208-233
  43. F. Pammolli, 2005, "The Growth of Business Firms: Theoretical Framework and Empirical Evidence", (with D. Fu, S.V. Buldyrev, M. Riccaboni, K. Yamasaki, K. Matia, H.E. Stanley) Proceedings of the National Academy of Sciences, 102(52), 18801-18806 (cover article)
  44. F. Pammolli, 2005, "Medical Devices Competitiveness and Impact on Public Health Expenditure", (with M. Riccaboni, C. Oglialoro, L. Magazzini, N. Salerno, G. Baio), Entreprise Directorate-General, European Commission, Bruxelles.
  45. F. Pammolli, 2005, "Pharmaceuticals Analysed through the Lens of a Sectoral Innovation System", (with M. McKelvey, L. Orsenigo), Part II.3 in F. Malerba (Ed.), Sectoral Systems of Innovation. Concepts, Issues and Analyses of Six Major Sectors in Europe, Cambridge University Press
  46. F. Pammolli, 2004, "Statistical Properties of Business Firm Structure and Growth", (with K. Matia, D. Fu, S. V. Buldyrev, M. Riccaboni), Europhysics Letters, 67(3), 493-503
  47. F. Pammolli, 2004, "Market Structure and Drug Innovation", (with M. Riccaboni), Health Affairs, 23(1), 48-50
  48. F. Pammolli, 2004, "The Nature and Extent of the Market for Technology in Biopharmaceuticals" (with A. Arora, A. Gambardella, M. Riccaboni), Part 2, pp. 175-202, in F. Cesaroni, A. Gambardella e W. Garcia-Fontes (Eds.), R&D, Innovation and Competitiveness in the European Chemical Industry, Springer, Dordrecht, NL
  49. F. Pammolli, 2004, "Dynamic Competition in Pharmaceuticals: On Patent Expiry, Generic Penetration and Industry Structure", (with L. Magazzini, M. Riccaboni), European Journal of Health Economics, 5(2), 175-182
  50. F. Pammolli, 2004, "Technological Competencies in Networks of Innovators", (with M. Riccaboni), Chap. 6 in J. Cantwell, A. Gambardella, O. Granstrand (Eds.) The Economics and Management of Technological Diversification. Routledge studies in the modern world economy, Routledge, London, UK
  51. F. Pammolli, 2003, "On Size and Growth of Business Firms", (with G. De Fabritiis, M. Riccaboni) Physica A, 324(1-2), pp. 38-44
  52. F. Pammolli, 2003, "Technological Regimes and the Evolution of Networks. Lessons from Biotechnology and Pharmaceuticals", (with M. Riccaboni), International Journal of Technology Management, 25(3), pp. 334-349
  53. F. Pammolli, 2003, "Technological Paradigms and the Evolution of Networks: Lessons from the Pharmaceutical Industry", (with M. Riccaboni), Chap. 2 in P. P. Saviotti (Ed.), Applied Evolutionary Economics: New Empirical Methods and Simulation Techniques, Edward Elgar, Cheltenham
  54. F. Pammolli, 2003, "Public Research and Industrial Innovation: A comparison of U.S. and European Innovation Systems in the Life Sciences", (with J. Owen-Smith, W.W. Powell, M. Riccaboni), Chap. 10 in A. Geuna, A. Salter, E. Steinmueller, (Eds.), Science and Innovation: Rethinking the Rationales for Funding and Governance, Edward Elgar, Cheltenham
  55. F. Pammolli, 2002, "Innovation and Competitiveness in European Biotechnology", (with A. Allansdottir, A. Bonaccorsi, A. Gambardella, M. Mariani, L. Orsenigo, , M. Riccaboni), Enterprise Papers n. 7, Enterprise Directorate-General, European Commission, Bruxelles. The paper is also available at: http://ec.europa.eu/enterprise/library/enterprise-papers/pdf/enterprise_paper_07_2002.pdf
  56. F. Pammolli, 2002, "Technological Regimes and the Growth of Networks: An Empirical Analysis", (with M. Riccaboni), Small Business Economics, 19(3), 205-215
  57. F. Pammolli, 2002, "The Intensity of Competition after Patent Expiry in Pharmaceuticals: a Cross-country Analysis", (with L. Magazzini, L.Orsenigo), Revue d'Economie Industrielle, 99, 107-132
  58. F. Pammolli, 2002, "A Comparison of U.S. and European University-Industry Relations in the Life Sciences", (with J. Owen-Smith, W.W. Powell, M. Riccaboni), Management Science, 48(1), 24-43. Also in M. McKelvey & L. Orsenigo (Eds.), The Economics of Biotechnology, Volume II, 342-361, Edward Edgar, Cheltenham
  59. F. Pammolli, 2002, "On Firm Growth in Networks", (with M. Riccaboni), Research Policy, 31(8-9), 1405-1416
  60. F. Pammolli, 2002, "Europe and the United States: The Power of Networks. Lessons from Technology Transfer", (with J. Owen-Smith, , W.W. Powell, M. Riccaboni ), Biofutur, 222, 26-29
  61. F. Pammolli, 2001, "The Nature and the Extent of Markets for Technology", (with A. Arora, A. Gambardella, M. Riccaboni), CNRS, Collection Les Cahiers de l'Innovation, Cahier n. 37
  62. F. Pammolli, 2001, "Innovation and Corporate Growth in the Evolution of the Drug Industry", (with G. Bottazzi, G. Dosi, M. Lippi, M. Riccaboni), International Journal of Industrial Organization, 19 (7), 1161-1187
  63. F. Pammolli, 2001, "Technological Change and Network Dynamics: Lessons from the Pharmaceutical Industry", (with L. Orsenigo, M. Riccaboni), Research Policy, 30(3), 485-508. Also in M. McKelvey & L. Orsenigo (Eds.), The Economics of Biotechnology, Volume II, 172-198, Edward Edgar, Cheltenham, UK
  64. F. Pammolli, 2001, "Variety and Irreversibility in Scientific and Technological Systems: the Evolution of an Industry Network", (with L. Orsenigo, M. Riccaboni), in A. Nicita, U. Pagano (Eds.), The Evolution of Economic Diversity, Routledge, London, 216-239
  65. F. Pammolli, 2001, "Global Competitiveness in Pharmaceuticals: A European Perspective" (with A. Gambardella, L. Orsenigo), DG Enterprise, European Commission, 2001.
  66.  F. Pammolli, 1998, "The Evolution of Knowledge and the Dynamics of an Industry Network" (with A. Bonaccorsi, L. Orsenigo, M. Riccaboni, G. Turchetti), The Journal of Management and Governance, 1(2), 147-175
  67.  F. Pammolli, 1996, "The Changing Boundaries of System Companies" (with A. Bonaccorsi, S. Tani), The International Business Review, 5(6), 539-560

 

 

 

ADDITIONAL INFORMATION

 

Fabio is the President and Scientific Director of the CERM Foundation (www.cermlab.it), which since 2002 has produced several contributions in the analysis of the sustainability of the Italian welfare system, with particular reference to health and pensions.

Fabio has coordinated several research projects funded by the EU as well as by national and international agencies, associations, companies, and foundations. He was the originator and the principal investigator of EPRIS (European Pharmaceutical Regulation and Innovation Systems), for which he was awarded a multi year (2000-2009) unrestricted competitive grant by the Merck and Co. Foundation in the US.

He has given talks and invited lectures at, among the others: The Council of Foreign Relations, the Royal Institute of International Affairs, World Economic Forum, The Vatican, NBER, London School of Economics, MIT, Stanford University, Columbia University, Boston University, UC Berkeley, the OECD, The Italian Ministry of Treasury, École des Mines, École Polytechnique, The John’s Hopkins University, the AAAS.

From 2007 to 2009, he served as a member of the EUCAN (Europe and Canada) Advisory Board to the CEO of Pfizer Inc., providing strategic insight and advising on the feasibility and quality of specific programs and initiatives. Other members were Ambassador Richard Gardner, Pat Cox, Paul Adamson, Esko Aho, Pat Cox, Sir Donald Irvine, Otto Graf Lambsdorff, Noëlle Lenoir, Julian Garcia Vargas, Hugo Paemen, Thomas Tindemans, Rob Woznow (Canada).

In the early 2000s he served a member of the Scientific Advisory Board for Research an Innovation in Confindustria, Rome, where he analyzed science and innovation policies.

Since jan, 2016, he’s a member of the Board of Trustees of Galleria dell’Accademia, Florence.

He has served as a columnist for the Corriere della Sera (2010-onwards), while in the past his editorials were published on Il Sole 24 Ore (2008-9).